Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Louis Potier

Showing results (41-50 of 97) with videos related to

Pageof 10
Sort By:
The Journal of Clinical Endocrinology and Metabolism|April 7, 2016
Plasma Copeptin, AVP Gene Variants, and Incidence of Type 2 Diabetes in a Cohort From the CommunityRonan Roussel, Ray El Boustany, Nadine Bouby, et al.
Journal of Diabetes|April 10, 2016
Outpatient measurement of arterial stiffness in patients with type 2 diabetes and obesityKamel Mohammedi, Aminata Compaoré, Louis Potier, et al.
Heart (British Cardiac Society)|March 13, 2017
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high vascular riskLouis Potier, Ronan Roussel, Yedid Elbez, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 18, 2013
Selective kinin receptor agonists as cardioprotective agents in myocardial ischemia and diabetesLouis Potier, Ludovic Waeckel, Marie-Pascale Vincent, et al.
Cardiovascular Diabetology|August 4, 2018
Plasma copeptin, kidney disease, and risk for cardiovascular morbidity and mortality in two cohorts of type 2 diabetesGilberto Velho, Stéphanie Ragot, Ray El Boustany, et al.
European Journal of Preventive Cardiology|May 1, 2014
Interaction between diabetes and a high ankle-brachial index on mortality riskLouis Potier, Ronan Roussel, Julien Labreuche, et al.
Genes and Immunity|November 18, 2023
Genetic variants of interferon-response factor 5 are associated with the incidence of chronic kidney disease: the D.E.S.I.R. studyFrédéric Fumeron, Gilberto Velho, Fawaz Alzaid, et al.
International Journal of Clinical Practice|September 25, 2020
Switching between GLP-1 receptor agonists in clinical practice: Expert consensus and practical guidanceAkshay B Jain, Amar Ali, Juan J Gorgojo Martínez, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|July 9, 2018
Glycosuria amount in response to hyperglycaemia and risk for diabetic kidney disease and related events in Type 1 diabetic patientsCharlyne Carpentier, Séverine Dubois, Kamel Mohammedi, et al.
Diabetes Care|October 5, 2019
Plasma Copeptin and Risk of Lower-Extremity Amputation in Type 1 and Type 2 DiabetesLouis Potier, Ronan Roussel, Michel Marre, et al.
Pageof 10

Showing results (41-50 of 97) with videos related to

Sort By:
Pageof 10
The Journal of Clinical Endocrinology and Metabolism|April 7, 2016
Plasma Copeptin, AVP Gene Variants, and Incidence of Type 2 Diabetes in a Cohort From the CommunityRonan Roussel, Ray El Boustany, Nadine Bouby, et al.
Journal of Diabetes|April 10, 2016
Outpatient measurement of arterial stiffness in patients with type 2 diabetes and obesityKamel Mohammedi, Aminata Compaoré, Louis Potier, et al.
Heart (British Cardiac Society)|March 13, 2017
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high vascular riskLouis Potier, Ronan Roussel, Yedid Elbez, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 18, 2013
Selective kinin receptor agonists as cardioprotective agents in myocardial ischemia and diabetesLouis Potier, Ludovic Waeckel, Marie-Pascale Vincent, et al.
Cardiovascular Diabetology|August 4, 2018
Plasma copeptin, kidney disease, and risk for cardiovascular morbidity and mortality in two cohorts of type 2 diabetesGilberto Velho, Stéphanie Ragot, Ray El Boustany, et al.
European Journal of Preventive Cardiology|May 1, 2014
Interaction between diabetes and a high ankle-brachial index on mortality riskLouis Potier, Ronan Roussel, Julien Labreuche, et al.
Genes and Immunity|November 18, 2023
Genetic variants of interferon-response factor 5 are associated with the incidence of chronic kidney disease: the D.E.S.I.R. studyFrédéric Fumeron, Gilberto Velho, Fawaz Alzaid, et al.
International Journal of Clinical Practice|September 25, 2020
Switching between GLP-1 receptor agonists in clinical practice: Expert consensus and practical guidanceAkshay B Jain, Amar Ali, Juan J Gorgojo Martínez, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|July 9, 2018
Glycosuria amount in response to hyperglycaemia and risk for diabetic kidney disease and related events in Type 1 diabetic patientsCharlyne Carpentier, Séverine Dubois, Kamel Mohammedi, et al.
Diabetes Care|October 5, 2019
Plasma Copeptin and Risk of Lower-Extremity Amputation in Type 1 and Type 2 DiabetesLouis Potier, Ronan Roussel, Michel Marre, et al.
Pageof 10